Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBITDA (2016 - 2025)

Abeona Therapeutics has reported EBITDA over the past 15 years, most recently at -$20.3 million for Q4 2025.

  • Quarterly results put EBITDA at -$20.3 million for Q4 2025, down 120.98% from a year ago — trailing twelve months through Dec 2025 was $71.3 million (up 212.02% YoY), and the annual figure for FY2025 was $71.3 million, up 212.02%.
  • EBITDA for Q4 2025 was -$20.3 million at Abeona Therapeutics, down from -$5.1 million in the prior quarter.
  • Over the last five years, EBITDA for ABEO hit a ceiling of $108.9 million in Q2 2025 and a floor of -$46.7 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$12.0 million (2023), compared with a mean of -$8.8 million.
  • Biggest five-year swings in EBITDA: crashed 250.5% in 2024 and later surged 1359.97% in 2025.
  • Abeona Therapeutics' EBITDA stood at -$46.7 million in 2021, then surged by 84.57% to -$7.2 million in 2022, then crashed by 129.78% to -$16.6 million in 2023, then surged by 44.43% to -$9.2 million in 2024, then crashed by 120.98% to -$20.3 million in 2025.
  • The last three reported values for EBITDA were -$20.3 million (Q4 2025), -$5.1 million (Q3 2025), and $108.9 million (Q2 2025) per Business Quant data.